Literature DB >> 2543335

Synthesis of epidermolysis bullosa acquisita antigen by simian virus 40-transformed human keratinocytes.

N Okada1, S Miyagawa, Y Horiguchi, Y Kitano, K Yoshikawa, K Sakamoto, M L Steinberg.   

Abstract

The synthesis of epidermolysis bullosa acquisita (EBA) antigen in simian virus 40 (SV40)-transformed human epidermal keratinocytes was studied. Indirect immunofluorescent staining of SV40-transformed keratinocytes employing a serum sample from an EBA patient as a source of antibodies decorated EBA antigen as a perinuclear granular fluorescence. This staining pattern was similar to that of nontransformed epidermal keratinocytes grown in a low Ca2+ medium. In contrast, stratified primary cultures of keratinocytes stained after growth in a high Ca2+ medium showed only small amounts of the antigen localized in the substrate-attached basal cells. To demonstrate biosynthesis of the EBA antigen by SV40-transformed keratinocytes, cells were metabolically labeled with 14C-amino acids and the cell lysates were immunoprecipitated with EBA antiserum. Analysis of immunoprecipitates by sodium dodecylsulfate-polyacrylamide gel electrophoresis and fluorography revealed that the EBA serum precipitated a protein with an apparent molecular weight of 290 kD from extracts of these cells. These results indicate that SV40 induces the synthesis of the 290 kD EBA antigen. Expression of this antigen may be a general feature of nonstratifying, proliferating epidermal cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543335     DOI: 10.1007/bf00424264

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  23 in total

1.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

2.  Discrepancy between the localization of in vivo bound immunoglobulins in the skin and in vitro binding sites of circulating anti-BMZ antibodies in bullous pemphigoid: immunoelectron microscopic studies.

Authors:  Y Horiguchi; S Imamura
Journal:  J Invest Dermatol       Date:  1986-12       Impact factor: 8.551

3.  The epidermal basement membrane zone--structure, ontogeny, and role in disease.

Authors:  S I Katz
Journal:  J Am Acad Dermatol       Date:  1984-12       Impact factor: 11.527

4.  Transformation and immortalization of human keratinocytes by SV40.

Authors:  M L Steinberg; V Defendi
Journal:  J Invest Dermatol       Date:  1983-07       Impact factor: 8.551

5.  Organ-specific, phylogenetic, and ontogenetic distribution of the epidermolysis bullosa acquisita antigen.

Authors:  A S Paller; L L Queen; D T Woodley; A T Lane; W R Gammon; R A Briggaman
Journal:  J Invest Dermatol       Date:  1986-04       Impact factor: 8.551

6.  Identification and partial characterization of pemphigoid antigen extracted from normal human skin.

Authors:  J R Stanley; D T Woodley; S I Katz
Journal:  J Invest Dermatol       Date:  1984-01       Impact factor: 8.551

7.  Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin.

Authors:  W R Gammon; R A Briggaman; A O Inman; L L Queen; C E Wheeler
Journal:  J Invest Dermatol       Date:  1984-02       Impact factor: 8.551

8.  The course of culture of human keratinocytes: increase of heat-labile fraction of glucose-6-phosphate dehydrogenase.

Authors:  Y Kitano; N Okada
Journal:  Acta Derm Venereol       Date:  1981       Impact factor: 4.437

9.  Epidermolysis bullosa acquisita. Immunofluorescence, electron microscopic and immunoelectron microscopic studies in four patients.

Authors:  C Nieboer; D M Boorsma; M J Woerdeman; G L Kalsbeek
Journal:  Br J Dermatol       Date:  1980-04       Impact factor: 9.302

10.  Re-expression of differentiated properties in SV40-infected human epidermal keratinocytes induced by 5-azacytidine.

Authors:  N Okada; M L Steinberg; V Defendi
Journal:  Exp Cell Res       Date:  1984-07       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.